AMEX:MTNB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Matinas BioPharma Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MTNB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.1%

MTNB

-3.0%

US Biotechs

-1.3%

US Market


1 Year Return

21.4%

MTNB

33.9%

US Biotechs

18.5%

US Market

Return vs Industry: MTNB underperformed the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: MTNB exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

MTNBIndustryMarket
7 Day-3.1%-3.0%-1.3%
30 Day7.5%1.8%5.3%
90 Day1.6%-3.7%7.5%
1 Year21.4%21.4%36.2%33.9%21.3%18.5%
3 Year-24.2%-24.2%19.1%13.1%42.4%32.9%
5 Year8.0%8.0%15.2%7.0%84.2%63.5%

Price Volatility Vs. Market

How volatile is Matinas BioPharma Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Matinas BioPharma Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MTNB ($0.86) is trading below our estimate of fair value ($5.84)

Significantly Below Fair Value: MTNB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MTNB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MTNB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MTNB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MTNB is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Matinas BioPharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

47.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MTNB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MTNB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MTNB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MTNB's revenue (94.2% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: MTNB's revenue (94.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MTNB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Matinas BioPharma Holdings performed over the past 5 years?

-8.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MTNB is currently unprofitable.

Growing Profit Margin: MTNB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MTNB is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.

Accelerating Growth: Unable to compare MTNB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: MTNB has a negative Return on Equity (-28.33%), as it is currently unprofitable.


Next Steps

Financial Health

How is Matinas BioPharma Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MTNB's short term assets ($69.2M) exceed its short term liabilities ($2.4M).

Long Term Liabilities: MTNB's short term assets ($69.2M) exceed its long term liabilities ($3.9M).


Debt to Equity History and Analysis

Debt Level: MTNB is debt free.

Reducing Debt: MTNB currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MTNB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MTNB has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 13.3% each year.


Next Steps

Dividend

What is Matinas BioPharma Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MTNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MTNB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MTNB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTNB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MTNB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Jerry Jabbour (46 yo)

2.58yrs

Tenure

US$1,325,176

Compensation

Mr. Jerome D. Jabbour, also known as Jerry, J.D., Co Founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016. M ...


CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD1.33M) is about average for companies of similar size in the US market ($USD1.27M).

Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jerome Jabbour
Co-Founder2.58yrsUS$1.33m0.21%
$ 366.6k
Keith Kucinski
Chief Financial Officer1.75yrsUS$626.60k0.048%
$ 81.6k
Theresa Matkovits
Chief Development Officer2yrsUS$698.14kno data
James Ferguson
Chief Medical Officer1.67yrsUS$810.77kno data
Raphael Mannino
Chief Scientific Officer5.08yrsUS$294.64k0.72%
$ 1.2m
Ian Cooney
Director of Investor Relations & Corporate Developmentno datano datano data
Frank Calamusa
Executive Director and Head of Manufacturing & Supply Chain2yrsno datano data

2.0yrs

Average Tenure

53yo

Average Age

Experienced Management: MTNB's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jerome Jabbour
Co-Founder2.58yrsUS$1.33m0.21%
$ 366.6k
Patrick LePore
Independent Vice Chairman of the Board2.08yrsUS$160.00k0.20%
$ 345.6k
Herbert Conrad
Independent Chairman of the Board7.25yrsUS$176.00k2.24%
$ 3.8m
Adam Stern
Director7.25yrsUS$130.00k2.94%
$ 5.1m
James Scibetta
Independent Director6.92yrsUS$155.00k0.31%
$ 536.6k
David Perlin
Member of Scientific Advisory Board5.25yrsno datano data
Christie Ballantyne
Member of Scientific Advisory Board1.83yrsno datano data
Matthew Wikler
Independent Director2.75yrsUS$143.50k0.12%
$ 201.0k
Eric Ende
Independent Director3.5yrsUS$151.50k0.058%
$ 99.6k
J. Craft
Member of Scientific Advisory Boardno datano datano data
Peter Pappas
Member of Scientific Advisory Boardno datano datano data
Kevin Maki
Member of Scientific Advisory Boardno datano datano data

3.5yrs

Average Tenure

56yo

Average Age

Experienced Board: MTNB's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MTNB insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.5%.


Top Shareholders

Company Information

Matinas BioPharma Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Matinas BioPharma Holdings, Inc.
  • Ticker: MTNB
  • Exchange: AMEX
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$171.872m
  • Shares outstanding: 198.95m
  • Website: https://www.matinasbiopharma.com

Number of Employees


Location

  • Matinas BioPharma Holdings, Inc.
  • 1545 Route 206 South
  • Suite 302
  • Bedminster
  • New Jersey
  • 7921
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTNBAMEX (NYSE MKT LLC)YesCommon StockUSUSDJun 2014
6LJDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2014

Biography

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 23:49
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.